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Edited by Judit Ova´diAbstract Here, we report the N-terminal glycine (Gly) residue
of a target protein can be a candidate primary amine for site-spe-
ciﬁc protein conjugation catalyzed by microbial transglutamin-
ase (MTG) from Streptomyces mobaraensis. Gly5-enhanced
green ﬂuorescent protein (EGFP) (EGFP with ﬁve additional
Gly residues at its N-terminus) was cross-linked with Myc-dihy-
drofolate reductase (DHFR) (DHFR with the myc epitope se-
quence at its N-terminus) to yield DHFR–EGFP heterodimers.
The reactivities of additional peptidyl linkers were investigated
and the results obtained suggested that at least three additional
Gly residues at the N-terminus were required to yield the
EGFP–DHFR heterodimeric form. Site-directed mutagenesis
analysis revealed marked preference of MTG for amino acids
adjacent to the N-terminal Gly residue involved in the protein
conjugation. In addition, peptide–protein conjugation was dem-
onstrated by MTG-catalyzed N-terminal Gly-speciﬁc modiﬁca-
tion of a target protein with the myc epitope peptide.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Site-speciﬁc protein modiﬁcation has been a powerful
strategy in biological research, because it enables protein
manipulation without signiﬁcant loss of function. Chemical
modiﬁcation is widely employed, although this strategy is
not always ‘‘site-speciﬁc’’ but rather ‘‘residue-speciﬁc’’. If
the target protein has a number of reactive residues, chemi-
cally modiﬁed products are often heterogeneous due to ran-
dom modiﬁcations. Since cysteine (Cys) residues do not
occur frequently in native proteins and a genetically intro-
duced Cys represents only one site to be modiﬁed, Cys-
based protein modiﬁcation with thiol-selective reagents has
often been employed [1]. Native chemical ligation, such asAbbreviations: DHFR, dihydrofolate reductase; EGFP, enhanced
green ﬂuorescent protein; MTG, microbial transglutaminase
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doi:10.1016/j.febslet.2005.02.064N-terminally introduced Cys-speciﬁc modiﬁcation, is a more
sophisticated strategy due to its capability of N-terminal-spe-
ciﬁc modiﬁcation [2,3]. One obstacle is the diﬃculty associ-
ated with producing Cys-introduced proteins due to the
formation of inclusion bodies or incorrect disulﬁde bridges
[4].
Enzymatic approaches to site-speciﬁc protein modiﬁcation
have attracted much attention because the substrate speciﬁcity
of an enzyme enables ‘‘site-speciﬁc’’ protein modiﬁcation. We
have focused on transglutaminase, a protein-modifying
enzyme that catalyzes an acyl transfer reaction between the
c-carboxyamine group of glutamine (Gln) residues and the e-
amino group of lysine (Lys) residues or various primary
amines [5]. Microbial transglutaminase (MTG) from Strepto-
myces mobaraensis has been widely employed due to its cal-
cium independency, handling feasibility and availability of
mass production by the microorganism [6]. The capability of
posttranslational protein modiﬁcation allows a range of pro-
teins to be engineered [7–13]. For instance, poly(ethylenegly-
col)-modiﬁed human interleukin 2 [12] and a single chain
variable fragment-alkaline phosphatase conjugate [13] were
successfully obtained. Brieﬂy, a short substrate sequence with
a Gln residue for MTG was genetically introduced at the
N-terminus of the target protein. The expressed protein was
modiﬁed with a small primary amine-containing molecule, or
conjugated with another target protein with a Lys residue by
MTG. The advantages of this enzymatic protein modiﬁcation
strategy are that it is highly selective and mild compared to
conventional methods.
In fact, although, it has been claimed that the substrate spec-
iﬁcity of MTG is comparatively low [14,15], in our experience,
MTG is reluctant to catalyze the cross-linking reaction of most
globular proteins. Additionally, Matsumura et al. [16] reported
that a-lactalbumin was subjected to the cross-linking reaction
only when a Ca2+ ion, which stabilizes its native structure, was
excluded from the reaction medium, suggesting that the
appearance of the molten globule state in the apoprotein plays
a key role in the substrate recognition by MTG. These ﬁndings
imply that the incorporation of speciﬁc peptide tags for MTG
recognition into proteins makes it possible to perform MTG-
mediated site-speciﬁc modiﬁcation or conjugation of func-
tional proteins unless intrinsic MTG-reactive Lys and Gln
residues are available in properly folded target proteins. How-
ever, the variation of peptidyl tags as substrates for MTG is
currently limited because the substrate speciﬁcity of MTG
has not yet been clearly established [17–20].
In this study, we demonstrate expansion of MTG-mediated
protein conjugation by N-terminal glycine (Gly)-speciﬁcblished by Elsevier B.V. All rights reserved.
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rescent protein (EGFP) with ﬁve additional Gly residues at its
N-terminus was employed as a model protein. Dihydrofolate
reductase (DHFR) with a myc epitope peptide at its N-termi-
nus was used as a partner protein in the protein conjugation.
Although, the myc epitope peptide possesses both Gln and
Lys residues (amino acid sequence: EQKLISEEDL), MTG
only recognizes the Gln residue and the myc peptide, therefore,
works as a Gln donor. Using this pair of proteins, we have
optimized the extra N-terminal amino acid sequence of the tar-
get protein and demonstrate highly eﬃcient amine-speciﬁc
labeling of proteins other than at Lys residues.Fig. 1. Extra N-terminal amino acid sequences of GlyX-EGFP, Myc-
DHFR and Myc/Q2N-DHFR (the myc epitope sequence is under-
lined).2. Materials and methods
2.1. Materials
Semi-puriﬁed MTG was provided by Ajinomoto Co. Inc. (Japan).
All other reagents were of the highest purity commercially available.
2.2. Sample preparation
DHFR carrying the myc epitope at its N-terminus (Myc-DHFR)
was prepared as follows. The gene coding DHFR was cloned from
Escherichia coli XL1-Blue (Stratagene) by PCR with Pyrobest DNA
polymerase (TAKARA, Japan). The primer sequences were 5 0-CAC
CAT CAT CAT CAT CAT TCT TCT GGT CTG GTG CCA CGC
GGT TCT GGT ACC GGA TCC ATG ATC AGT CTG ATT
GCG GCG TTA GCG and 5 0-GCC GAG CTC CTA AGC GGC
CGC CCG CCG CTC CAG AAT CTC AAA GCA ATA GC. The
ampliﬁed gene fragment containing a His-tag, thrombin cleavage site
and DHFR was cloned into the pBAD/thio-TOPO vector (Invitrogen)
and the resultant plasmid was designated pBAD-DHFR. The se-
quences were veriﬁed using an SQ-5500 sequencer (Hitachi, Japan).
Next, PCR was performed using pBAD-DHFR as a template. The pri-
mer used was 5 0-GGG GTA CCG AAC AGA AAC TGA TCT CTG
AAG AAG ACC TGG GAT CCA TGA TCA GTC TGA TTG CGG
CG and the second primer described above. The ampliﬁed fragment
coding Myc-DHFR was cloned into pBAD-DHFR with KpnI/SacI
double-digestion and the resultant plasmid was designated pBAD-
Myc-DHFR. EGFPs with an additional peptide at the N-terminus
(GlyX-EGFP) were prepared in a similar manner. First, EGFP carry-
ing ﬁve additional Gly (Gly5-EGFP) was prepared. The gene encoding
a Factor Xa cleavage site, ﬁve additional Gly and EGFP were obtained
by PCR using pEGFP (Clontech) as a template and cloned into
pBAD-DHFR with KpnI/SacI double-digestion. The primer sequences
were 5 0-GGG GTA CCG GTA TTG AGG GTC GCG GCG GTG
GAG GTG GTA TGG TGA GCA AGG GCG AGG AGC TGT
TC and 5 0-GCG AGC TCA GCG GCC GCC TAC TTG TAC
AGC TCG TCC ATG CCG AGA GTG ATC CC. The resultant plas-
mid was designated pBAD-Gly5-EGFP. Site-directed mutagenesis
analysis was then carried out using a QuikChange site-directed
mutagenesis kit (Stratagene) with pBAD-Gly5-EGFP or pBAD-
Myc-DHFR as a template. The primer sequences were as follows: 5 0-
GGT ACC GGT ATT GAG GGT CGC GCC GGT GGA GGT
GGT ATG GTG AGC (AlaG4-EGFP), 5 0-GGT ACC GGT ATT
GAG GGT CGC GGC GGT GGT ATG GTG AGC AAG GGC
GAG GAG CTG TTC (Gly3-EGFP), 5 0-GGT ACC GGT ATT
GAG GGT CGC GGT ATG GTG AGC AAG GGC GAG GAG
CTG TTC (Gly1-EGFP), 5 0-GGT ACC GGT ATT GAG GGT
CGC GGC CGT GGA GGT GGT ATG GTG AGC AAG GGC
GAG G (GRG3-EGFP), 5 0-GGT ACC GGT ATT GAG GGT
CGC GGC GAA GGA GGT GGT ATG GTG AGC AAG GGC
GAG G (GEG3-EGFP), 5 0-GGT ACC GGT ATT GAG GGT
CGC GGC TTC GGA GGT GGT ATG GTG AGC AAG GGC
GAG G (GFG3-EGFP), 5 0-GGT ACC GGT ATT GAG GGT
CGC GGC ATG GTG GGT GGT ATG GTG AGC AAG GGC
GAG G (GMVGG-EGFP), 5 0-GGT ACC GGT ATT GAG GGT
CGC GGT GGC GGC AGC AAG GGC GAG GAG CTG TTC
(GGG-D EGFP), 5 0-G CCA CGC GGT TCT GGT ACC GAA
AAC AAG CTG ATC TCT GAA GAA GAC C (Myc/Q2N-DHFR)and their complementary strands. The DNA sequences encoding the
mutation sites are underlined. The amino acid sequences of the N-ter-
minal additional peptides are summarized in Fig. 1.
Protein expression was induced in E. coli strain Top10 (Invitrogen)
by addition of 0.1% L-arabinose and subsequent incubation for 16 h at
27 C. The fusion proteins were puriﬁed using TALON metal aﬃnity
resin (Clontech) as described previously [19]. The puriﬁed proteins
were subjected to site-speciﬁc cleavage with thrombin or Factor Xa
(both from Novagen) to eliminate the thioredoxin in the N-terminus
of the fusion proteins. The concentrations of MTG and DHFR were
determined using a BCA assay kit (Pierce). In the case of the recombi-
nant EGFPs, the protein concentrations were determined as reported
previously [19].
2.3. Peptide synthesis
The myc peptide (amino acid sequence: EQKLISEEDLGC) was
synthesized by stepwise solid-phase synthesis using Fmoc chemistry.
The peptide sequence was veriﬁed using a Voyager-DE STR MALDI
TOF spectrometer (PE-ABI) and puriﬁed using a YMC-Pack ODS-
A C18 column on a HPLC (JASCO, Japan).
2.4. Protein cross-linking reactions between recombinant DHFR and
EGFP by MTG
Myc-DHFR (10 lM) or Myc/Q2N-DHFR (20 lM) and GlyX-
EGFP (40 lM) were dissolved in 10 mM sodium phosphate buﬀer
(pH 7.5), and the cross-linking reaction was initiated by addition of
MTG (0.012 U/mL). After incubation for 24 h at 4 C, the reaction
was terminated by mixing with SDS–PAGE sample buﬀer (50 mM
Tris–HCl, 2% SDS, 6% 2-mercaptoetahnol) and boiling. The samples
were then subjected to SDS–PAGE and the gels were stained with
Coomassie brilliant blue R-250 (Sigma). Image analysis of the stained
gels was performed with Scion Image (Scion Corporation). The density
of the EGFP–DHFR heterodimeric form was normalized by the value
obtained with Gly1-EGFP.
2.5. Labeling procedure of Gly5-EGFP with the myc peptide
Gly5-EGFP (10 lM) and myc peptide (40 lM) were dissolved in
10 mM sodium phosphate buﬀer (pH 7.5), and the labeling reaction
was initiated by addition of MTG (0.012 U/mL). After 24 h incubation
at 4 C, the reaction was terminated as described above and analyzed
by Western blotting with an anti-myc antibody (Bethyl laboratories).3. Results and discussion
Our previous studies showed that wild-type EGFP does not
contain any reactive Lys or Gln residues for MTG, which
makes it suitable for characterization of MTG-mediated pro-
tein cross-linking through a speciﬁc peptide genetically fused
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speciﬁc protein heterodimerization by SDS–PAGE analyses,
E. coli DHFR was employed as a partner protein to be
cross-linked because there is a distinct diﬀerence in molecular
weight between EGFP (ca. 28 kDa) and DHFR (ca. 18 kDa).
First, it was conﬁrmed that DHFR itself did not contain any
reactive Gln and Lys that were recognized by MTG (data
not shown), suggesting that it is a good candidate for a partner
protein. Next, we designed and prepared a variety of recombi-
nant EGFPs and DHFR with an N-terminal Gly (Fig. 1).
3.1. N-terminal Gly-speciﬁc conjugation of Gly5-EGFP with
Myc-DHFR
Fig. 2 shows the eﬀect of MTG treatment on Myc-DHFR.
Myc-DHFR homodimerization was observed, implying that
both Lys and Gln in the fused myc peptide are involved in
the cross-linking reaction (lanes 2 and 3 in Fig. 2). To test if
Gln in the myc tag is reactive in the protein conjugation, we
prepared myc tag-Gln deﬁcient mutant, Myc/Q2N-DHFR. It
was found that Myc/Q2N-DHFR was not susceptible to
MTG treatment, indicating that Gln in the myc tag works as
a Gln donor (lanes 8 and 9 in Fig. 2). However, the Myc-
DHFR homodimerization was not prevented by amino acid
substitution of the Lys in the myc tag to Arg (data not shown).
Since there is no reactive Lys in DHFR itself, we assumed that
the a-amino group of the N-terminal Gly residue may be in-
volved in the cross-linking reaction (see Fig. 1). To conﬁrm
this, Gly5-EGFP with ﬁve additional Gly residues at its N-ter-
minus was prepared. Judging from both the molecular mass of
the product (ca. 46 kDa) and the reduced intensity of the Myc-
DHFR protein band (lane 5 in Fig. 2), Myc-DHFR and Gly5-
EGFP were cross-linked by MTG to yield the corresponding
heterodimer. When the N-terminal Gly of Gly5-EGFP was re-
placed with Ala (AlaG4-EGFP), the heterodimerization was
completely abolished and the Myc-DHFR homodimerization
was regained (lanes 6 and 7 in Fig. 2). These results indicate
that the a-amino group of the N-terminal Ala residue cannot
be recognized by MTG as a substrate, suggesting the eﬀect
of steric hindrance by the side chain of the N-terminal Ala
on the N-terminal protein cross-linking by MTG. Ohtsuka
et al. [20] studied the reactivity of small primary amine deriv-Fig. 2. SDS–PAGE analysis of the reaction products after MTG
treatment: lane 1, molecular weight markers; lane 2, Myc-DHFR; lane
3, Myc-DHFR treated with MTG; lane 4, Myc-DHFR and Gly5-
EGFP; lane 5, Myc-DHFR and Gly5-EGFP treated with MTG; lane
6, Myc-DHFR and AlaG4-EGFP; lane 7, Myc-DHFR and AlaG4-
EGFP treated with MTG; lane 8, Myc/Q2N-DHFR and Gly5-EGFP;
lane 9, Myc/Q2N-DHFR and Gly5-EGFP treated with MTG.atives and suggested that steric hindrance around a reactive
amino group has a crucial eﬀect on the catalytic activity of
MTG.
3.2. Evaluation of the cross-linking eﬃciency of GlyX-EGFP
We further explored N-terminal-speciﬁc protein conjugation
by changing the number of additional Gly residues at the N-
terminus. EGFPs possessing one, three or ﬁve Gly residues
at the N-terminus were prepared. Fig. 3B shows that the pres-
ence of three Gly residues at the N-terminus resulted in a 10-
fold enhancement compared with that of a single Gly residue.
A slight increase in the reactivity was observed when the linker
length was further increased to ﬁve Gly residues (Gly5-EGFP).
These results indicate that a ﬂexible peptidyl linker of a suit-
able length is required for the N-terminal protein cross-linking.
There are two possible explanations for the low reactivity of
Gly1-EGFP. The ﬁrst is that the second Met and third Val res-
idues from the N-terminus of Gly1-EGFP (corresponding to
Met1 and Val2 of wild-type EGFP) are unfavorable for the
N-terminal cross-linking reaction. The second is that just one
Gly residue alone is insuﬃciently reactive for recognition by
MTG. For better understanding of this phenomenon, we pre-
pared two types of mutants, GGG-DEGFP and GMVGG-Fig. 3. (A) SDS–PAGE analysis of the reaction products after MTG
treatment of a mixture of Myc-DHFR and GlyX-EGFP. Molecular
weight markers are shown in lane 1. Lanes with odd numbers show the
results of MTG treatment of Myc-DHFR with Gly5-EGFP (lane 3),
Gly3-EGFP (lane 5), Gly1-EGFP (lane 7), GRG3-EGFP (lane 11),
GEG3-EGFP (lane 13) or GFG3-EGFP (lane 15). Lanes with even
numbers show the corresponding control experiments without MTG
(for instance, lane 2 should be compared with lane 3). The result of
MTG treatment of Myc-DHFR in the absence of GlyX-EGFP is
shown in lane 9. (B) Image analysis of polyacrylamide gels stained with
Coomassie brilliant blue. The band intensities of the EGFP–DHFR
heterodimeric forms were normalized by the value obtained with Gly1-
EGFP.
Fig. 5. Western blotting analysis of N-terminal-labeled Gly5-EGFP
with the myc peptide catalyzed by MTG: lane 1, Gly5-EGFP and myc
peptide; lane 2, Gly5-EGFP and myc peptide treated with MTG.
T. Tanaka et al. / FEBS Letters 579 (2005) 2092–2096 2095EGFP. GGG-DEGFP has three additional Gly, but the ﬁrst
two residues of wild-type EGFP, Met1 and Val2, are deleted.
GMVGG-EGFP has ﬁve additional amino acids, Gly–Met–
Val–Gly–Gly, at the N-terminus of EGFP (see Fig. 1). As
shown in Fig. 4, the reactivity of GGG-DEGFP was inferior
to that of Gly3-EGFP (lanes 4 and 5 in Fig. 3A), suggesting
that a spacer region is required to separate the N-terminal
Gly from the original sequence of the target protein. In con-
trast, the cross-linking eﬃciency of GMVGG-EGFP was very
low despite the ﬁve additional residues at its N-terminus,
implying that the type of amino acid next to the N-terminal
Gly residue has a dominant eﬀect on the N-terminal protein
conjugation.
Hence, we checked the eﬀect of the second amino acid on the
eﬃciency of the protein conjugation. Basic (Arg), acidic (Glu)
and bulky (Phe) residues were introduced as the second amino
acid from the N-terminus of Gly5-EGFP (Fig. 1). As shown in
Fig. 3B, substitution of the second amino acid produced a sub-
stantial decrease in the eﬃciency of protein cross-linking. In
particular, when Glu was introduced, the corresponding pepti-
dyl linker exhibited the lowest reactivity and was comparable
to Gly1-EGFP, despite the fact that it had ﬁve additional res-
idues at the N-terminus. On the other hand, substitution with a
basic amino acid increased the reactivity of GRG3-EGFP
compared to GEG3-EGFP and GFG3-EGFP. These results
are consistent with those in our previous study [21] and the
substrate preference of MTG suggested by its tertiary structure
[22].
Another fraction of Myc-DHFR was observed around its
monomeric form when less reactive EGFP variants (Gly1-
EGFP and GEG3-EGFP) were employed. This fraction could
be ascribed to a byproduct formed by competitive hydrolysis
of Gln to Glu (deamidation) catalyzed by MTG, which in-
creases the negative charge of the myc epitope sequence of
Myc-DHFR.
3.3. N-terminal-speciﬁc labeling of proteins with a short peptide
Site-speciﬁc protein modiﬁcation with small organic mole-
cules is useful for all biological and biotechnological ﬁelds ofFig. 4. SDS–PAGE analysis of the N-terminal conjugate of GMVGG-
EGFP or GGG-DEGFP with Myc-DHFR: lane 1, molecular weight
markers; lane 2 2, Myc-DHFR and GMVGG-EGFP; lane 3, Myc-
DHFR and GMVGG-EGFP treated with MTG; lane 4, Myc-DHFR
and GGG-DEGFP; lane 5, Myc-DHFR and GGG-DEGFP treated
with MTG.research. Transglutaminase-mediated protein modiﬁcations
have been conducted between proteins containing reactive
Gln residues and organic molecules containing a primary
amine [12,23]. Here, we have demonstrated N-terminal Gly-
speciﬁc labeling of proteins with a small molecule by MTG.
As shown in Fig. 5, when the myc epitope peptide was incu-
bated with Gly5-EGFP, the N-terminal Gly of Gly5-EGFP
was successfully labeled with the peptide, as evaluated by Wes-
tern blotting analysis. This ﬁnding clearly shows the possibility
of N-terminal-speciﬁc protein labeling with small organic mol-
ecules without using a primary amine.
In conclusion, we have developed N-terminal Gly-speciﬁc
protein modiﬁcation by MTG. It was easy to generate an N-
terminal Gly by in vitro protease cleavage as demonstrated
in this study, and this can also probably be achieved by in vivo
aminopeptidase-mediated processing [24]. At least three addi-
tional Gly residues appeared to be necessary to ensure good
reactivity for the N-terminal protein conjugation. To the best
of our knowledge, the peptide with three Gly residues is the
shortest peptidyl tag reported to date for TG-mediated protein
modiﬁcation. The new strategy for N-terminal protein conju-
gation proposed here will be useful for the creation of novel
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